We’re proud to welcome The Leukemia & Lymphoma Society - Eastern Pennsylvania & Delaware Region Board of Trustees member, Donna Hunt Hodge! 🙌 🥰 Donna is currently the Vice President, Sales, Marketing, and Operations, US CAR-T with Johnson & Johnson Innovative Medicine. In this role, Donna oversees all commercial functions of the J&J Cell Therapy organization, ensuring that those who are eligible for their best-in-class treatments are able to access and benefit from these life-enhancing therapies. Committed to improving the health and quality of life for patients around the world, Donna has spearheaded 10 product launches in 6 therapeutic areas, covering a wide-ranging list of innovative medicines. In her current role, she continues to dedicate herself to the relentless pursuit of putting patients first – providing potentially curative therapies and developing high-potential talent to deliver them. Please join us in dropping a note of thanks and congratulations to Donna today in the comments! ❤️👇
The Leukemia & Lymphoma Society - Eastern Pennsylvania & Delaware Region’s Post
More Relevant Posts
-
Exciting developments in the oncology landscape! The FDA’s priority review of acalabrutinib (Calquence) for previously untreated mantle cell lymphoma signals significant progress in treatment options. With data indicating a 27% reduction in disease progression risk, this could transform patient outcomes. For healthcare marketers, understanding these innovations will be crucial in crafting impactful narratives that resonate with both patients and providers. Let's explore the implications together.
-
3 Reasons why you should attend the Lymphoma, Leukemia & Myeloma Congress this October: 1. Enhancing relationships with your colleagues and meeting new peers that share the same interest 2. Gain direct access to industry experts to advance your connections and knowledge 3. Learning about new advancements and best practices in hematologic malignancies to best treat your patients. Why wait to register? Rates increase after August 2: https://lnkd.in/e2i8XbKr #llmcongress2024 #lymphoma #leukemia #myeloma #bloodcancers #oncology #education #networking #patientcare
Available Dates
hmpglobalevents.com
-
September is World Leukemia and Lymphoma Awareness Month. On behalf of Aptitude Health, patients, caregivers, and HCPs, we commemorate the importance of groundbreaking research and therapies in #Leukemia, #Lymphoma, #Myeloma, and #Myelofibrosis. #BloodCancerAwareness
-
-
Multiple myeloma is the third-largest blood cancer by patient numbers globally, after lymphoma and leukemia, including afflicting 9.7 individuals per 100,000 each year in the US. Incidence is on a rising trend, with variable rates across regions. The rate is higher in richer countries, but this is likely driven by better diagnostics and capacity, further boosted by the availability of multiple drugs. Bloomberg's 2024 Myeloma report will cover: > Bristol Myers Loses Myeloma Crown > J&J-Genmab’s Darzalex Dominance > CAR-T Race Heats up > Bispecifics Add More Breakthroughs To download the full report click on the link below. Alternatively email me directly at jbrowne8@bloomberg.net https://lnkd.in/eugR3Ukc
-
World Lymphoma Awareness Day (WLAD) is observed on September 15th every year. It is a day dedicated to raising awareness and understanding about lymphoma, a type of cancer that affects the lymphatic system. The aim of World Lymphoma Awareness Day is to increase public knowledge about lymphoma, its symptoms, diagnosis, and treatment options. It also aims to support those affected by lymphoma, including patients, families, and caregivers. This year marks the 20th anniversary of WLAD and the theme is “Honest Talk,” focusing on the emotional effects of living with lymphoma. The campaign encourages open conversations between patients, healthcare providers, and loved ones to address emotional concerns and foster supportive relationships. #IQVIA, #WeAreIQVIA, #clinicalresearch
-
CAR T Therapy: A Path of Hope and Healing For over 7 years, CAR T therapy has offered renewed hope to thousands of patients with multiple myeloma, large B lymphoma, and other forms of lymphoma and leukemia. PIXACORE is proud to partner with The Leukemia & Lymphoma Society (LLS) to present an inspiring new docuseries on the power of CAR T therapy. This series raises awareness of this transformative treatment, showcasing its profound impact on patient outcomes, access to care, and community engagement. We are thrilled to announce that the full docuseries, "CAR T Therapy: A Path of Hope and Healing," is now available! Thank you to LLS, Dr. Carl June, and our sponsors Kite, Bristol Myers Squibb, and Johnson & Johnson & LEGEND BIOTECH for making this vision a reality. Watch the full docuseries here: https://lnkd.in/ebMT29dU #CARTCellTherapy #celltherapy #Leukemia #Lymphoma #LLS #PIXACORE #ASH2024 #Myeloma #DLBCL
-
“Excited to share our recent case report on a rare presentation of Oropharyngeal Burkitt Lymphoma. This aggressive yet treatable form of non-Hodgkin lymphoma requires timely diagnosis and management. Our report highlights key clinical features, challenges in diagnosis, and successful therapeutic interventions. Excited to contribute to the growing body of knowledge in oncology, with the hope of enhancing early recognition and treatment outcomes. #Oncology #BurkittLymphoma #MedicalResearch #LymphomaAwareness #Healthcare”
-
✨ New discovery: autoantibodies in Hodgkin's lymphoma ✨ Researchers from EUROIMMUN and international partners have identified anti-RGS8 autoantibodies associated with a rare subtype of Hodgkin's lymphoma and severe cerebellar ataxia. 📌 Key Facts: Rare autoantibodies, mostly in middle-aged men. Associated with nodular lymphocyte-predominant Hodgkin's lymphoma. Affected patients often respond poorly to immunotherapy. These findings could be groundbreaking fordiagnostics and treatment of rare paraneoplastic syndromes. If you want to know more, you can find all the details in our blog article : https://lnkd.in/dUwDgfvn #Hodgkin'slymphoma #RGS8 #neuroimmunology #research #EUROIMMUN
-
-
Advancing Care for Older Adults with Non-Hodgkin Lymphoma Treating older adults with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), requires balancing efficacy and safety amidst age-related challenges. Two recent studies presented at the American Society of Hematology (ASH) Annual Meeting offer actionable insights: 1. Comprehensive Geriatric Assessment (CGA) identified frailty-related risks that traditional ECOG performance scores missed, enabling better therapy personalization. 2. Timed Up and Go (TUG) Test reliably predicted chemotherapy toxicity, with abnormal times linked to higher toxicity risks and poorer survival outcomes. Incorporating these tools into routine practice could enhance outcomes by tailoring treatments to individual needs, particularly in vulnerable populations, suggesting the future of oncology care for older adults lies in personalized, data-driven approaches. Learn more! #Hematology #NonHodgkinLymphoma #PrecisionMedicine #ASH2024
Experienced Sales Professional
3moCongrats Donna!